FIRST TRIMESTER SCREENING FOR PREECLAMPSIA – A SYSTEMATIC REVIEW

References

• Duley L. The global impact of preeclampsia and eclampsia. Semin Perinatol. 2009;33:130–137.
   PubMed Web of Science ®Google Scholar
• Bell MJ. A historical overview of preeclampsia-eclampsia. J Obstet Gynecol Neonatal Nurs. 2010;39:510–518.
   PubMed Web of Science ®Google Scholar
• Ghossein-Doha C, van Neer J, Wissink B, et al. Preeclampsia, an important female specific risk factor for asymptomatic heart failure. UOG. 2017;49:143–149.
   Google Scholar
• Sehqal A, Skilton MR, Crispi F. Human fetal growth restriction: a cardiovascular journey through to adolescence. J Dev Orig Health Dis. 2016;7:626–635.
   PubMed Web of Science ®Google Scholar
• Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy. Obstet Gynecol. 2010;116:402–414.
   PubMed Web of Science ®Google Scholar
• Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. AJOG. 2018;218:287–93.e1.
   PubMed Web of Science ®Google Scholar
• Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565.
   PubMed Web of Science ®Google Scholar
• Wright D, Akolekar R, Syngelaki A, et al. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. 2012;32:171–178.
   PubMed Web of Science ®Google Scholar
• National institute of health and care excellence. Hypertension in pregnancy: diagnosis and management. Clinical Guideline CG107. January 2011
   Google Scholar
• ACOG committee opinion no. 743: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;32:e44–e52.
   Google Scholar
• Wright D, Syngelaki A, Akolekar R, et al. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. AJOG. 2015;213:62.e1–62.e10.
   Web of Science ®Google Scholar
• Akolekar R, Etchegaray A, Zhou Y, et al. Maternal serum activin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther. 2009;25:320–327.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn. 2008;28:212–216.
   PubMed Web of Science ®Google Scholar
• Akolekar R, Minekawa R, Veduta A, et al. Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:753–760.
   PubMed Web of Science ®Google Scholar
• Scazzocchio E, Figueras F, Crispi F, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. AJOG. 2013;208:203.e1–203.e10.
   PubMed Web of Science ®Google Scholar
• Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8–15.
   PubMed Web of Science ®Google Scholar
• O’Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. AJOG. 2016;214:103.e1–103.e12.
   PubMedGoogle Scholar
• Mosimann B, Amylidi-Mohr S, Höland K, et al. Importance of timing first-trimester placental growth factor and use of serial first-trimester placental growth factor measurement in screening for preeclampsia. Fetal Diagn Ther. 2017;42:111–116.
   PubMed Web of Science ®Google Scholar
• Crovetto F, Figueras F, Triunfo S, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters and angiogenic factors. Prenat Diagn. 2015;35:183–191.
   PubMed Web of Science ®Google Scholar
• Chafetz I, Kuhnreich I, Sammar M, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. AJOG. 2007;197:35.e1–35.e7.
   PubMed Web of Science ®Google Scholar
• Baumann MU, Bersinger NA, Mohaupt MG, et al. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. AJOG. 2008;199:266.e1–266.e6.
   PubMed Web of Science ®Google Scholar
• Leal AM, Poon LC, Frisova V, et al. First-trimester maternal serum tumor necrosis factor receptor-1 and preeclampsia. Ultrasound Obstet Gynecol. 2009;33:135–141.
   PubMed Web of Science ®Google Scholar
• Eastering TR, Benedetti TJ, Schmucker BC, et al. Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol. 1990;76:1061–1069.
   PubMed Web of Science ®Google Scholar
• Valensise H, Vasapollo B, Gagliardi G, et al. Early and late preeclamapsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008;52:873–880.
   PubMed Web of Science ®Google Scholar
• Khalil AA, Cooper DJ, Harrington KF. Pulse wave analysis: apreliminary study of a novel technique for the prediction of preeclampsia. BJOG. 2009;116:268–277.
   PubMed Web of Science ®Google Scholar
• Osman MW, Nath M, Breslin E, et al. Association between arterial stiffness and wave reflection with subsequent development of placental mediated diseases during pregnancy: findings of a systematic review and meta-analysis. J Hypertens. 2018;36:1005–1014.
   PubMed Web of Science ®Google Scholar
• Poon LC, Zymeri NA, Zamprakou A, et al. Protocol for measurement of mean arterial pressure at 11–13 weeks’ gestation. Fetal Diagn Ther. 2012;31:42–48.
   PubMed Web of Science ®Google Scholar
• Binder J, Monaghan C, Thilaganathan B, et al. De-novo abnormal uteroplacental circulation in third trimester: pregnancy outcome and pathological implications. Ultrasound Obstet Gynecol. 2018;52:60–65.
   PubMed Web of Science ®Google Scholar
• www.fetalmedicine.org/research/assess/preeclampsia
   Google Scholar
• Ridding G, PJ S, JA H, et al. Influence of sampling site on uterine artery Doppler indices at 11–13+6 weeks gestation. Fetal Diagn Ther. 2015;37:310–315.
   PubMed Web of Science ®Google Scholar
• Herzog EM, Eggink AJ, Reijnierse A, et al. Impact of early- and late-onset preeclampsia on features of placental and newborn vascular health. Placenta. 2017;49:72.
   PubMed Web of Science ®Google Scholar
• Nelson DB, Ziadie MS, McIntire DD, et al. Placental pathology suggesting that preeclampsia is more than one disease. AJOG. 2014;210:66.e1–66.e7.
   PubMed Web of Science ®Google Scholar
• Arleo EK, Troiano RN, da Silva R, et al. Utilizing two-dimensional ultrasound to develop normative curves for estimated placental volume. Am J Perinatol. 2014;31:683–688.
   PubMed Web of Science ®Google Scholar
• Rani S, Huria A, Kaur R. Prediction of perinatal outcome in preeclampsia using middle cerebral artery and umbilical artery pulsatility and resistance indices. Hypertens Pregnancy. 2016;35:210–216.
   PubMed Web of Science ®Google Scholar
• Baschat AA, Magder LS, Doyle LE, et al. Prediction of preeclampsia utilizing the first trimester screening examination. AJOG. 2014;211:514.e1–514.e7.
   Web of Science ®Google Scholar
• www.medicinafetalbarcelona.org/calc
   Google Scholar
• Kleinrouweler CE, Cheong-See FM, Collins GS, et al. Prognostic models in obstetrics: available, but far from applicable. AJOG. 2016;214:79–90.e36.
   PubMed Web of Science ®Google Scholar
• Farina A, Rapacchia G, Freni Sterrantino A, et al. Prospective evaluation of ultrasound and biochemical-based multivariable models for the prediction of late preeclampsia. Prenat Diagn. 2011;31:1147–1152.
   PubMed Web of Science ®Google Scholar
• Oliveira N, Magder LS, Blitzer MG, et al. First-trimester prediction of preeclampsia: external validity of algorithms in a prospectively enrolled cohort. UOG. 2014;44:279–285.
   Google Scholar
• Allen RE, Zamora J, Arroyo-Manzano D, et al. External validation of preexisting first trimester preeclampsia prediction models. Eur J Obstet Gynecol Reprod Biol. 2017;217:119–125.
   PubMed Web of Science ®Google Scholar
• Herraiz I, Arbues J, Camano I, et al. Application of a first-trimester prediction model for preeclampsia based on uterine arteries and maternal history in high-risk pregnancies. Prenat Diagn. 2009;29:1123–1129.
   PubMed Web of Science ®Google Scholar
• Goetzinger KR, Tuuli MG, Cahill AG, et al. Development and validation of a risk factor scoring system for first trimester prediction of preeclampsia. Am J Perinatol. 2014;31:1049–1056.
   PubMed Web of Science ®Google Scholar
• Francisco C, Wright D, Benko Z, et al. Competing risks model in screening for preeclampsia in twin pregnancies by maternal characteristics and medical history. UOG. 2017;50:501–506.
   Google Scholar
• Francisco C, Wright D, Benko Z, et al. Competing-risks model in screening for preeclampsia in twin pregnancy according to maternal factors and biomarkers at 11–13 weeks’ gestation. UOG. 2017;50:589–595.
   Google Scholar
• Maymon R, Trahtenherts A, Svirsky R, et al. Developing a new algorithm for first and second trimester preeclmapsia screening in twin pregnancies. Hypertens Pregnancy. 2017;36:108–115.
   PubMed Web of Science ®Google Scholar
• Tan MY, Wright D, Syngelaki A, et al. Comparison of diagnostic accuracy of early screening for preeclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51:743–750.
   PubMed Web of Science ®Google Scholar
• Brunelli VB, Prefumo F. Quality of first trimester risk prediction models for preeclampsia: a systematic review. BJOG. 2015;122:904–914.
   PubMed Web of Science ®Google Scholar
• Wright D, Tan MY, O’Gorman N, et al. Predictive performance of the competing risk model in screening for preeclampsia. AJOG. 2019;220:199.e1–199.e13.
   Web of Science ®Google Scholar
• O’Gorman N, Wright D, Rolnik DL, et al. Study protocol for the randomized controlled trial: combined multimarker screening and randomized patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open. 2016;6:e011801.
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. NEJM. 2017;377:613–622.
   PubMed Web of Science ®Google Scholar
• Meher S, Duley L, Hunter K, et al. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. AJOG. 2017;216:121–8.e2.
   PubMed Web of Science ®Google Scholar
• Poon LC, Rolnik DL, Tan MY, et al. ASPRE trial: incidence of preterm preeclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. UOG. 2018;51:738–742.
   Google Scholar
• Poon LC, Wright D, Rolnik DL, et al. Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetric history. AJOG. 2017;217:585.e1-e5.
   Web of Science ®Google Scholar
• Wright D, Poon LC, Rolnik DL, et al. Aspirin for evidence-based preeclampsia prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. AJOG. 2017;217:685.e1-e5.
   Web of Science ®Google Scholar
• Wright D, Rolnik DL, Syngelaki A, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. AJOG. 2018;218:612.e1-e6.
   Web of Science ®Google Scholar